Autologous Multi-lineage Potential Cells (AMPC) are unique stem cells used in procedures facilitated by ASC Treatment. They are superior to existing stem cells used for treatment due to their coveted combination of features:
AMPC are extracted from the recipient’s blood, and will be recognised by the recipient’s body, eliminating transplant rejection risk.
They are pluripotent stem cells, and can be used for a wide range of conditions, including those treated with HSC and MSC. This bypasses the need for separate stem cell treatments to be sought.
The AMPC culture produces a naturally high cell count so that treatment will be effective. More cells will be available for regeneration and repair purposes.
Stem Cell Treatment Process
ASC’s stem cell treatment procedure is streamlined into a three-step process where you undergo assessments, choose an option, and experience the revolutionary treatment.
A pre-assessment of the patient’s body will first be conducted. This will help us better understand your body condition as everyone’s health conditions are unique.
You fill first be asked to complete a general health assessment form while we analyse your medical history. A pathology test for your blood quality will also be assessed to optimise your stem cell treatment.
After we have determined your physical health and compatibility with the stem cell treatment. We will tailor the best course of reinfusion depending on your condition. Depending on your requirements, you may choose to undergo:
Intravenous Stem Cell Reinfusion
This is the most commonly sought form of treatment where stem cell reinfusion takes place intravenously. The bloodstream acts as a highway used by stem cells to travel to most parts of the body, barring the brain where a natural physical barrier protects it from potential harm.
In intravenous stem cell reinfusions, the stem cells will seek out damaged parts of the body to carry out regeneration and repair functions. This has resulted in reinvigoration, reinforced immune systems, and general wellness in patients.
Joint Injection for Arthritis Treatment
Joint injections involve the direct delivery of stem cells into a joint for arthritis treatment. Patients with arthritis or sports injuries have reported pain alleviation after stem cell treatments. The high cell counts and pluripotent capability of our stem cells will prove more effective than conventional mesenchymal stem cell arthritis treatments.
For those who wish to restore a youthful and radiant appearance to their skin, facial injections of our stem cells may provide the solution.
The cultured stem cells have been administered in past patients who reported improved complexion. In particular, wrinkles, facial lines, and sagging skin were reduced through the rejuvenating stem cells.
3. Stem Cell Reinfusion and Treatment
Each treatment with ASC begins with an extraction of blood. Approximately 250mL to 400mL of blood will be drawn for culture purposes, depending on patient fitness. Generally, the more blood drawn, the more stem cells will be cultured for stem cell reinfusion. The blood is then delivered directly to the laboratory for processing.
The collected blood will then be converted into stem cells at high cell counts. A timeline of the conversion process can be found here.
iii. Stem Cell Reinfusion
Stem cell reinfusion may take place immediately after culture on the 5th day post blood collection. Prior to that, a pre-injection for allergies will be conducted to ensure smooth stem cell delivery. Depending on your chosen route of administration, the stem cell reinfusion process may vary.
- For intravenous stem cell reinfusions, the stem cells are injected intravenously, similar to blood collection. This will be completed within 2 to 3 hours.
- For joint injections, a highly concentrated dose of the stem cells will be directly injected into the target joint.
- For cosmetic procedures, the stem cells will be injected subcutaneously onto the skin. Mesotherapy delivery is also conducted after a skin needling procedure.
The production process of AMPC is unique to ASC Treatment. Existing stem cell treatment providers have yet to produce a pluripotent stem cell with of AMPC’s calibre. Our safety is also unparalleled as we have ample measure to safeguard all patients from adverse effects.
- No genetic manipulation – AMPC production does not require any genetic manipulation of any kind. Whereas traditional methods of producing pluripotent stem cell requires genetic manipulation which may cause mutation risks into cancerous cells.
- Relatively uninvasive – Only intravenous blood collection which is similar to blood donation and reinfusion intravenously through drips is required for undergoing AMPC stem cell treatment. Painful surgical bone marrow extractions, liposuction or transplants are forgone for this relatively painless procedure. This means risk of surgical complications are eliminated.
- Closed system – The closed system culture environment of the stem cells reduces frequency of contact with the external environment. Once collected in sterile blood bags, the blood, and subsequently cultured stem cells, are no longer exposed to the environment, thus minimising the risk of contamination.
- NATA-laboratory screenings – All samples to be used for treatment are also screened by laboratories external to ASC Treatment. These laboratories are accredited by the National Association of Testing Authorities (NATA) and must provide desirable test results before any samples are released for treatment.
- Vero Insurance – Vero Insurance, one of Australia’s largest medical insurers, also insures all stem cell procedures facilitated by ASC Treatment for up to a sum of AUD 20 million. This reflects the high safety profile of the stem cells.